Company news
CRISPR Therapeutics AG news in 2022
CRISPR Therapeutics AG's news releases, calls and decks from 2022, newest first.
CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development
December 18, 2022
CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON™ Trial of CTX110®
December 11, 2022
Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition
December 9, 2022
CRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference
November 30, 2022
CRISPR Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
November 9, 2022
CRISPR Therapeutics Announces Poster Presentation on CTX110® at the American Society of Hematology (ASH) 2022 Annual Meeting
November 2, 2022
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
October 31, 2022
CRISPR Therapeutics Announces Planned Transition of Chief Operating Officer
October 26, 2022
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
October 4, 2022
CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy
September 28, 2022
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)
September 27, 2022
Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
September 26, 2022
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
August 7, 2022
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress
June 10, 2022
CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress
June 10, 2022
CRISPR Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
June 7, 2022
Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress
June 1, 2022
CRISPR Therapeutics to Host Innovation Day on June 21, 2022
May 30, 2022
CRISPR Therapeutics Announces the Appointment of Phuong Khanh Morrow, M.D., FACP, as Chief Medical Officer
May 15, 2022
CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress
May 11, 2022
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
May 8, 2022
CRISPR Therapeutics to Present at the 2022 Bank of America Healthcare Conference
May 3, 2022
CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2022 Annual Meeting
March 7, 2022
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
February 14, 2022
CRISPR Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
February 8, 2022
CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)
February 1, 2022
Decks in 2022
- Investor Day (June 2022)
Investor day · 6 slides · Jun 21, 2022
- Technical Presentation (June 2022)
Technical · 16 slides · Jun 13, 2022
- Investor Presentation (2022)
Investor deck · 42 slides · 2022